Understanding Knee Joint Wear
Cartilage covers the ends of the bones in the knee, enabling smooth movement and absorbing the load of everyday activity. It has a limited capacity to repair itself after injury or progressive wear, which is why even partial loss can cause persistent pain, stiffness and reduced mobility. The earlier the joint is assessed, the more options are typically available — ranging from non-surgical support to, where appropriate, more involved intervention.
What Is ChondroFiller?
ChondroFiller is a Class III CE-marked medical device manufactured by Meidrix Biomedicals in Germany. It is an acellular (cell-free) type I collagen hydrogel scaffold: a dual-component formulation that, when injected, gels in situ within approximately three to five minutes, filling the contours of the cartilage defect. Once in place, the scaffold acts as a chemotactic matrix, recruiting the patient's own progenitor cells from the surrounding tissue and subchondral bone to migrate into and repopulate the defect. Over time, those cells may differentiate and deposit new extracellular matrix, supporting hyaline-like cartilage repair. The scaffold itself is gradually resorbed, typically over one to two years.
It is important to understand what ChondroFiller is not. It does not contain cells, growth factors or stem cells in its injected form, and it is not a guarantee of cartilage regrowth. It is best described as a biologically active scaffold that gives the joint's own repair mechanisms a structural foundation to work from.
The ChondroFiller Injection: A Non-Surgical Pathway
The ChondroFiller injection is a non-surgical, outpatient procedure. There is no incision, no theatre, and no general anaesthetic. The collagen scaffold is delivered into the knee joint under ultrasound guidance, which allows precise placement over the worn area. Patients can typically return home the same day and resume low-level activity relatively promptly, although individual recovery varies and will depend on the extent of joint wear and any concurrent treatment.
This non-surgical pathway suits patients with accessible lesions where the joint surface can be reached under imaging guidance — typically smaller cartilage defects or areas of generalised joint wear. It is particularly relevant for those who want a biologically active option beyond conventional injections (such as corticosteroids or hyaluronic acid) but who either do not need, or are not yet candidates for, more involved surgical intervention.
ChondroFiller should not be confused with Liquid Cartilage. Liquid Cartilage is Professor Paul Lee's keyhole surgical protocol, a separate and more involved procedure performed in theatre, which combines the ChondroFiller scaffold with biological adjuncts and, where appropriate, the patient's own mesenchymal stem cells. Liquid Cartilage is surgery; the ChondroFiller injection is not. Which pathway is suitable depends on the individual patient's anatomy, defect size, and clinical picture.
What the Evidence Suggests
ChondroFiller carries a Class III CE marking, which reflects the highest risk class for a medical device and requires a rigorous clinical evaluation before approval. Published clinical experience demonstrates meaningful improvements in patient-reported outcomes. In knee applications, International Knee Documentation Committee (IKDC) scores have been reported to improve by approximately 30 points over 12 to 36 months in published series. Imaging using Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scoring has shown values in the range of 70 to 87, indicating good-quality tissue fill and integration at the defect site.
An independent case series published in 2023 reported significant pain reduction and functional improvement following ChondroFiller use in trapeziometacarpal (thumb base) osteoarthritis (Corain et al., Cartilage, 2023), supporting the device's application across different joint types beyond the knee. The safety record from post-market data is notably strong; clinical studies and surveillance data report a near-zero rate of serious complications.
These figures represent outcomes from published series rather than promises about any individual's result. ChondroFiller does not cure osteoarthritis and does not reverse established joint degeneration. The aim is biologic support and joint preservation — which for some patients may delay or reduce the need for further intervention, while for others it may be one element of a broader management plan.
Who Might Benefit?
ChondroFiller injection may be appropriate for adults with knee osteoarthritis or focal cartilage wear who:
- want a non-surgical, biologically active option beyond standard injections
- have not achieved sufficient relief from more conservative measures such as physiotherapy, anti-inflammatory medication or hyaluronic acid injections
- have lesions that are accessible via an image-guided injection approach
- understand the realistic scope of the treatment and are not seeking a guaranteed cure
It is less likely to be the right choice for patients with very large defects, severe bone-on-bone osteoarthritis, or structural problems such as significant malalignment, where surgical assessment would be more appropriate. A thorough clinical evaluation, including imaging review, is necessary to determine suitability.
Assessment at the London Cartilage Clinic
At the London Cartilage Clinic, patients presenting with knee cartilage problems receive a structured assessment that reviews their clinical history, imaging and activity goals. The clinic's approach to joint preservation ranges from non-surgical injections — including the ChondroFiller injection — to the Liquid Cartilage surgical protocol for cases that require keyhole intervention. The role of the initial consultation is to identify which pathway, or combination of measures, best matches the patient's circumstances. For patients suited to the ChondroFiller injection, realistic expectations are set from the outset.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- Pain, stiffness, swelling and reduced range of movement are common, often developing gradually from injury, overuse or age-related degeneration. It is worth seeking a specialist opinion when symptoms affect daily activity, are not responding to rest and simple measures, or when you want to understand what non-surgical options may be available before the joint deteriorates further.
- The ChondroFiller injection is a non-surgical outpatient procedure with no incision and no general anaesthetic. The collagen scaffold is placed into the joint under ultrasound guidance. Liquid Cartilage, by contrast, is Professor Paul Lee's keyhole surgical protocol performed in theatre, which combines the same ChondroFiller scaffold with biological adjuncts and, where indicated, the patient's own stem cells. The two are distinct pathways; which is appropriate depends on the individual's clinical picture.
- ChondroFiller is an acellular type I collagen hydrogel. It contains no cells and no growth factors. When injected, it gels within three to five minutes, forming a scaffold that the patient's own progenitor cells can migrate into and repopulate. It is a Class III CE-marked medical device, reflecting a rigorous pre-approval clinical evaluation process.
- Adults with knee osteoarthritis or focal cartilage wear who want a non-surgical, biologically active option and have not had sufficient relief from more conservative measures may be suitable. A full clinical assessment — including review of imaging — is needed to confirm suitability. Patients with very large defects, severe end-stage arthritis or significant structural problems are more likely to need surgical evaluation.
- Published series report meaningful improvements in pain and function scores, with IKDC scores improving by approximately 30 points over 12 to 36 months in knee cases. MRI-based tissue quality assessments (MOCART scores) have shown good defect fill in published experience. However, ChondroFiller does not cure arthritis and does not reverse established joint loss. Results vary between individuals, and the aim is biologic support and joint preservation rather than guaranteed regrowth.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
